

World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2018 December 15; 10(12): 465-531





REVIEW

- 465 Current strategies for malignant pedunculated colorectal polyps
Ciocalteu A, Gheonea DI, Saftoiu A, Streba L, Dragoescu NA, Tenea-Cojan TS

ORIGINAL ARTICLE

Basic Study

- 476 Histological analysis of human pancreatic carcinoma following irreversible electroporation in a nude mouse model
Su JJ, Xu K, Wang PF, Zhang HY, Chen YL

Retrospective Study

- 487 Clutch Cutter knife efficacy in endoscopic submucosal dissection for early gastric neoplasms
Hayashi Y, Esaki M, Suzuki S, Ihara E, Yokoyama A, Sakisaka S, Hosokawa T, Tanaka Y, Mizutani T, Tsuruta S, Iwao A, Yamakawa S, Irie A, Minoda Y, Hata Y, Ogino H, Akiho H, Ogawa Y

- 496 Stents combined with iodine-125 implantation to treat main portal vein tumor thrombus
Wu YF, Wang T, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Liu FQ

Clinical Trials Study

- 505 Multicenter phase II trial of modified FOLFIRINOX in gemcitabin-refractory pancreatic cancer
Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer

CASE REPORT

- 516 Small intestinal hemangioma: Endoscopic or surgical intervention? A case report and review of literature
Hu PF, Chen H, Wang XH, Wang WJ, Su N, Shi B
- 522 Experience in the diagnosis and treatment of mesenteric lymphangioma in adults: A case report and review of literature
Chen J, Du L, Wang DR

LETTER TO THE EDITOR

- 528 Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
Sunakawa Y, Satake H, Ichikawa W

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Mao-Ming Xiong, MD, Professor, Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China

AIM AND SCOPE

World Journal of Gastrointestinal Oncology (World J Gastrointest Oncol, WJGO), online ISSN 1948-5204, DOI: 10.4251 is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJGO covers topics concerning carcinogenesis, tumorigenesis, metastasis, diagnosis, prevention, prognosis, clinical manifestations, nutritional support, molecular mechanisms, and therapy of benign and malignant tumors of the digestive tract. The current columns of *WJGO* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of gastrointestinal oncology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJGO*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

INDEXING/ABSTRACTING

World Journal of Gastrointestinal Oncology (WJGO) is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, and PubMed Central. The 2018 edition of Journal Citation Reports® cites the 2017 impact factor for *WJGO* as 3.140 (5-year impact factor: 3.228), ranking *WJGO* as 39 among 80 journals in gastroenterology and hepatology (quartile in category Q2), and 114 among 222 journals in oncology (quartile in category Q3).

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Han Song*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fang-Fang Ji*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL

World Journal of Gastrointestinal Oncology

ISSN

ISSN 1948-5204 (online)

LAUNCH DATE

February 15, 2009

FREQUENCY

Monthly

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <https://www.wjgnet.com/1948-5204/editorialboard.htm>

EDITORIAL OFFICE

Jin-Lei Wang, Director
World Journal of Gastrointestinal Oncology
 Baishideng Publishing Group Inc

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-2238242

Fax: +1-925-2238243

E-mail: editorialoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc

7901 Stoneridge Drive,
 Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-2238242

Fax: +1-925-2238243

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

PUBLICATION DATE

December 15, 2018

COPYRIGHT

© 2018 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors

Yu Sunakawa, Hironaga Satake, Wataru Ichikawa

Yu Sunakawa, Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan

Hironaga Satake, Cancer Treatment Center, Kansai Medical University Hospital, Hirakata-city, Osaka 573-1191, Japan

Wataru Ichikawa, Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Kanagawa 227-8501, Japan

ORCID number: Yu Sunakawa (0000-0002-0163-7543); Hironaga Satake (0000-0001-7629-6803); Wataru Ichikawa (0000-0001-5543-4488).

Author contributions: Sunakawa Y had full access to the data used in this study, drafted the paper, and had final responsibility for the decision to submit for publication; Sunakawa Y statistically analyzed the data; Satake H and Ichikawa W contributed to analysis and interpretation of the data; all authors contributed to the drafting or revision of the manuscript and have approved the final version.

Conflict-of-interest statement: Sunakawa Y has received honoraria from Taiho Pharmaceutical, Chugai Pharma, Yakult Honsha, Takeda, Merck Serono, Bayer Yakuhin, Eli Lilly Japan, and Sanofi; Satake H has received honoraria from Bayer, Chugai Pharma, Eli Lilly Japan, Merck Serono, Takeda, Taiho Pharmaceutical and Yakult Honsha; Ichikawa W has received honoraria from Chugai Pharma, Merck Serono, Takeda Pharmaceutical, and Taiho Pharmaceutical; research funding from Chugai Pharma, Takeda Pharmaceutical, and Taiho Pharmaceutical.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Corresponding author to: Yu Sunakawa, MD, PhD, Associate Professor, Department of Clinical Oncology, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan. y.suna0825@gmail.com
Telephone: +81-44-9778111
Fax: +81-44-9753755

Received: August 27, 2018

Peer-review started: August 27, 2018

First decision: September 11, 2018

Revised: September 17, 2018

Accepted: November 2, 2018

Article in press: November 2, 2018

Published online: December 15, 2018

Abstract

A recent subgroup analysis of the TRIBE trial suggested that FOLFOXIRI plus bevacizumab may be a preferred option for the first-line treatment of only right-sided metastatic colorectal cancer (mCRC), regardless of RAS or *BRAF* status. Our subanalysis of a phase II trial of the FOLFOXIRI triplet regimen plus bevacizumab in patients with mCRC who had RAS mutant tumors showed that tumor shrinkage was better and the duration of treatment was longer in patients with left-sided tumors than in those with right-sided tumors, leading to a higher rate of conversion to surgery in mCRC patients with left-sided tumors. The early and deep responses to the triplet-regimen in patients with left-sided tumors might facilitate conversion treatment resulting in favorable survival. Our data suggest that the FOLFOXIRI plus bevacizumab might be a promising treatment for left-sided mCRC involving RAS mutant tumors.

Key words: Tumor sidedness; FOLFOXIRI; Bevacizumab; Colorectal cancer; RAS mutation

© The Author(s) 2018. Published by Baishideng Publishing

Group Inc. All rights reserved.

Core tip: FOLFOXIRI plus bevacizumab regimen might be a preferred option for the first-line treatment of only right-sided metastatic colorectal cancer (mCRC) regardless of RAS or *BRAF* status. However, subanalysis of a phase II trial of the triplet plus bevacizumab in patients with RAS mutant mCRC demonstrated that more patients with left-sided tumors achieved good tumor shrinkage and long duration of treatment than did patients with right-sided tumors, leading to higher rate of conversion to surgery in mCRC patients with left-sided tumors. Our data suggest that FOLFOXIRI plus bevacizumab may be a promising treatment for left-sided mCRC associated with RAS mutant tumors.

Sunakawa Y, Satake H, Ichikawa W. Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors. *World J Gastrointest Oncol* 2018; 10(12): 528-531
URL: <https://www.wjgnet.com/1948-5204/full/v10/i12/528.htm>
DOI: <https://dx.doi.org/10.4251/wjgo.v10.i12.528>

TO THE EDITOR

A randomized study, the TRIBE trial, has demonstrated that FOLFOXIRI plus bevacizumab is more beneficial than FOLFIRI plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (mCRC). In addition, a number of clinical studies, including the STEAM and CHARTA trials, have shown similar clinical benefits of treatment with FOLFOXIRI plus bevacizumab^[1-3]. Therefore, the triplet-regimen is considered one of the standard first-line treatments for mCRC in the National Comprehensive Cancer Network and European Society for Medical Oncology consensus guidelines^[4,5]. Recently, a subgroup analysis of the TRIBE trial was performed to investigate the effect of upfront tumor sidedness on therapeutic effectiveness and whether this potentially heterogeneous effect differed according to RAS and *BRAF* mutational status in mCRC. The results indicated that patients who harbored right-sided tumors achieved an evident survival benefit from the triplet-regimen as backbone chemotherapy regardless of RAS and *BRAF* status. Namely, FOLFOXIRI plus bevacizumab can be considered to be a preferred treatment option in a first-line setting for only right-sided mCRC^[6].

The location of the primary tumor has an impact on clinical behavior and has prognostic value in mCRC. A recent meta-analysis suggested that tumor sidedness is a predictive marker of the response to anti-epidermal growth factor receptor (EGFR) therapy in patients with RAS wild-type mCRC. Patients with left-sided tumors were shown to derive a greater benefit from chemotherapy plus an anti-EGFR antibody than from chemotherapy plus bevacizumab, whereas right-sided tumors were associated with trends toward

detrimental effects of anti-EGFR therapy^[7]. Therefore, anti-EGFR therapy with cetuximab or panitumumab is recommended for only RAS wild-type and left-sided tumors. A subanalysis of the TRIBE trial according to tumor sidedness showed no higher survival benefit from a triplet-regimen as compared with a doublet-regimen in patients with RAS wild-type mCRC who had left-sided tumors, suggesting that a doublet-regimen plus an anti-EGFR antibody is the preferred treatment for patients with left-sided RAS wild-type tumors. On the other hand, in patients with RAS mutant tumors, which do no benefit from anti-EGFR antibodies, the question remains whether intensification of the triplet regimen plus bevacizumab should be limited to patients who have mCRC with right-sided tumors.

In the subgroup analysis of the TRIBE trial, the objective response rate (ORR) of the triplet-arm was 65.0% for left-side tumors and 62.5% for right-side tumors in patients with RAS mutant tumors. The median progression-free survival (PFS) was 12.5 mo for patients with left-side tumors and 11.0 mo for those with right-side tumors. The efficacy of intensive chemotherapy with bevacizumab did not appear to differ significantly between tumor sidedness in patients with RAS mutant mCRC. Moreover, in patients who had left-sided tumors with RAS mutation, the ORR and PFS were slightly but not significantly higher in the triplet-arm than in the doublet-arm.

We have conducted a phase II trial of first-line FOLFOXIRI plus bevacizumab for mCRC with RAS mutant tumors. The ORR was the primary endpoint, and the secondary endpoints included PFS, early tumor shrinkage (ETS), and depth of response (DpR). The ORR and ETS rates in enrolled patients were 75.8% and 73.8%, respectively. According to primary tumor side, the ORR and ETS were both much better in patients with left-sided tumors than in patients with right-sided tumors (82.2% vs 58.8%, 77.3% vs 64.7%, respectively)^[8]. Here, we performed an exploratory analysis of DpR using spider-plots in each tumor side. Interestingly, the spider-plots demonstrated that tumor shrinkage was better and the duration of treatment was longer in the patients with left-sided tumors than in those with right-sided tumors (Figure 1). One (6%) of 17 patients could undergo conversion surgery in the right-sided group, while 11 (28%) of 40 patients could receive conversion surgery in the left-sided group. The early and deep responses to the triplet regimen in the left-sided group may facilitate conversion treatment associated with favorable survival.

We showed an analysis of the evaluated radiographic responses to FOLFOXIRI plus bevacizumab for mCRC according to each tumor side using spider plots. Cremolini *et al.*^[9] has reported the association of ETS and DpR with clinical outcomes of triplet plus bevacizumab treatment using the TRIBE data; however, the results according to tumor sidedness have not been reported yet. Our phase II trial was a prospective




Figure 1 Spider plots of the response to 1st-line FOLFOXIRI plus bevacizumab in patients with RAS mutation (JACCRO CC-11). A: Spider plots of tumor burden changes in patients with left-sided tumors (*n* = 44); B: Spider plots of tumor burden changes in patients with right-sided tumors (*n* = 17).

study designed to evaluate the efficacy of FOLFOXIRI plus bevacizumab in molecular-selected patients with RAS mutation. Moreover, tumor response as a primary endpoint was evaluated prospectively by an external review board. Our findings for RAS mutant mCRC would be more reliable than the findings of the sub-analysis of the TRIBE trial. FOLFOXIRI plus bevacizumab was not beneficial in left-sided tumors in the TRIBE trial, while FOLFOXIRI plus bevacizumab appeared to be better compared to FOLFOX plus bevacizumab in left-sided tumors in other 2 trials^[2,3]. Types of backbone chemotherapy may affect the results of sub-analyses

by tumor sidedness. Although a recent study reported that FOLFOXIRI plus bevacizumab may be regarded as a preferred option for only right-sided mCRC^[6], our data suggest that the triplet-regimen may be a promising treatment for left-sided mCRC with RAS mutant tumors.

ACKNOWLEDGEMENTS

We thank the patients, their families, and the investigators who participated in the Japan Clinical Cancer Research Organization (JACCRO) CC-11 trial. We also thank JACCRO and Masashi Fujii for trial support.

REFERENCES

- 1 **Loupakis F**, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *N Engl J Med* 2014; **371**: 1609-1618 [PMID: 25337750 DOI: 10.1056/NEJMoa1403108]
- 2 **Hurwitz H**, Tan BR, Reeves JA, Xiong HQ, Somer BG, Lenz H-J, Hochster HS, Scappaticci F, Palma JF, Mancao C, Lee JJ, Nicholas A, Sommer N, Bendell JC. Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal cancer (mCRC). *J Clin Oncol* 2017; **35**: 657 [DOI: 10.1200/JCO.2017.35.4_suppl.657]
- 3 **Schmoll HJ**, Meinert FM, Cygon F, Garlipp B, Junghans C, Leithäuser M, Vogel A, Schaefer M, Kaiser U, Hoeffkes H-G, Florschütz A, Rüssel J, Kanzler S, Edelmann T, Forstbauer H, Goehler T, Hannig C, Hildebrandt B, Steighardt J, Stein A. "CHARTA": FOLFOX/Bevacizumab vs FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO. *J Clin Oncol* 2017; **35**: 3533 [DOI: 10.1200/JCO.2017.35.1_5_suppl.3533]
- 4 **Van Cutsem E**, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanen A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 2016; **27**: 1386-1422 [PMID: 27380959 DOI: 10.1093/annonc/mdw235]
- 5 **Yoshino T**, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. *Ann Oncol* 2018; **29**: 44-70 [PMID: 29155929 DOI: 10.1093/annonc/mdx738]
- 6 **Cremolini C**, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A. Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer. *Ann Oncol* 2018 [PMID: 29897402 DOI: 10.1093/annonc/mdy140]
- 7 **Arnold D**, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. *Ann Oncol* 2017; **28**: 1713-1729 [PMID: 28407110 DOI: 10.1093/annonc/mdx175]
- 8 **Satake H**, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T. A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11. *Oncotarget* 2018; **9**: 18811-18820 [PMID: 29721163 DOI: 10.18632/oncotarget.24702]
- 9 **Cremolini C**, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R, Zaniboni A, Tonini G, Barone C, Vitello S, Longarini R, Bonetti A, D'Amico M, Di Donato S, Granetto C, Boni L, Falcone A. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. *Ann Oncol* 2015; **26**: 1188-1194 [PMID: 25712456 DOI: 10.1093/annonc/mdv112]

P- Reviewer: Lin Q, Nahitendur MA, Saglam S **S- Editor:** Wang XJ
L- Editor: A **E- Editor:** Song H





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

